INT MEDICAL (01501) announced that on October 10, 2025 (after trading hours), the company entered into a subscription agreement with BRONCUS-B. Under the agreement, BRONCUS-B conditionally agreed to issue a total of 91,093,613 subscription shares to the company at a subscription price of HK$3.11 per subscription share, with a total consideration of HK$283,301,136.43 (excluding transaction costs), subject to the terms and conditions set out in the subscription agreement.

Upon completion, the company will hold a total of 91,093,613 BRONCUS-B shares, representing approximately 17.24% of BRONCUS-B's issued shares as of the announcement date (or approximately 17.30% excluding treasury shares) and approximately 14.38% of BRONCUS-B's enlarged issued shares following the issuance of subscription shares (or approximately 14.42% excluding treasury shares). BRONCUS-B's financial results will not be consolidated into the group's accounts.

The announcement stated that considering BRONCUS-B's rich product portfolio in the non-vascular intervention field, the subscription can further expand the company's strategic layout in the non-vascular intervention sector.